In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer
Bashir Lawal,1,2,* Yu-Cheng Kuo,3,4,* Maryam Rachmawati Sumitra,1,2 Alexander TH Wu,5– 8 Hsu-Shan Huang1,2,8– 10 1PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiw...
Guardado en:
Autores principales: | Lawal B, Kuo YC, Sumitra MR, Wu ATH, Huang HS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7cd4985fe3f04ce0a0fa9f6ceebb0cce |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Radicicol-Mediated Inhibition of Topoisomerase VIB-VIA Activity of the Human Malaria Parasite <named-content content-type="genus-species">Plasmodium falciparum</named-content>
por: Sureshkumar Chalapareddy, et al.
Publicado: (2016) -
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity
por: Dong D, et al.
Publicado: (2019) -
The Antileukemic Effect of Xestoquinone, A Marine-Derived Polycyclic Quinone-Type Metabolite, Is Mediated through ROS-Induced Inhibition of HSP-90
por: Kuan-Chih Wang, et al.
Publicado: (2021) -
New molecular biologist perspective and insight: DNA topoisomerases production by recombinant DNA technology for medical laboratory application and pharmaceutical industry
por: Chan,Mooi Kwai, et al.
Publicado: (2013) -
Topoisomerase-Mediated DNA Damage in Neurological Disorders
por: Morgan Crewe, et al.
Publicado: (2021)